NDUFA11
ENSG00000174886
Target class
Enzyme
Chromosome
19
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Limited
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- B14.7
- Target name
- NDUFA11
- Gene name
- NADH:ubiquinone oxidoreductase subunit A11
- Gene symbol
- NDUFA11
- Protein name
- NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11 (Complex I-B14.7) (CI-B14.7) (NADH-ubiquinone oxidoreductase subunit B14.7)
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits|Tim17 family
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 59.65
- Tissue specificity (Gini)
- 0.163
- Tissue specificity (tau)
- 0.328
- KEGG gene identifiers
- hsa:126328
- Protein interaction confidence
- 0.941964
- Protein interaction partners
- 83
- R-HSA-611105
- R-HSA-6799198
- End position
- 5904006
- Start position
- 5891207
- Chromosome
- 19
- Strand
- Reverse
- Mitochondrion inner membrane
- Multi-pass membrane protein
- Matrix side .
- End piece
- Mitochondria
- Perinuclear theca
- Principal piece
Publication evidence
- PubMed 12611891
- Tissue specificity (tau)
- 0.32827
- Expression inequality (Gini)
- 0.162918
Expression in transcripts per million
- Adrenal Gland
- 59.65
- Heart - Atrial Appendage
- 58.8
- Colon - Sigmoid
- 58.36
- Uterus
- 57.75
- Prostate
- 56.32
Expression in transcripts per million
- Adrenal Gland59.65
- Heart - Atrial Appendage58.8
- Colon - Sigmoid58.36
- Uterus57.75
- Prostate56.32
- Fallopian Tube55.69
- Esophagus - Gastroesophageal Junction55.31
- Esophagus - Muscularis54.96
- Thyroid54.02
- Cervix - Endocervix53.93
- Cervix - Ectocervix53.22
- Cells - Cultured fibroblasts49.93
- Vagina49.78
- Ovary49.61
- Artery - Aorta48.71
- Brain - Cerebellum47.54
- Brain - Cerebellar Hemisphere47.47
- Esophagus - Mucosa46.1
- Nerve - Tibial45.6
- Bladder45.32
- Kidney - Medulla45.19
- Artery - Coronary44.97
- Pituitary44.96
- Spleen44.47
- Cells - EBV-transformed lymphocytes44.23
And 29 more, listed on the interactive page.
- GO:0005739
- GO:0005743
- GO:0045271
Molecular functions
- GO:0005515
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor